You are here

  • Home
  • Archive
  • Volume 67, Issue 8
  • Is there any role for tumour necrosis factor related apoptosis inducing ligand–osteoprotegerin (TRAIL–OPG) interaction in rheumatoid arthritis?

Article Text

Article menu
Download PDFPDF
Letter
Is there any role for tumour necrosis factor related apoptosis inducing ligand–osteoprotegerin (TRAIL–OPG) interaction in rheumatoid arthritis?
  1. G Castellino1,
  2. F Corallini2,
  3. F Trotta1,
  4. P Secchiero2
  1. 1
    Rheumatology Section, Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy
  2. 2
    Human Anatomy Section, Department of Morphology and Embryology, University of Ferrara, Ferrara, Italy
  1. G Castellino, Rheumatology Section, Department of Clinical and Experimental Medicine, University of Ferrara, Corso della Giovecca 203, 44100 Ferrara, Italy; gabriella_castellino{at}yahoo.it

https://doi.org/10.1136/ard.2007.081067

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with great interest the article “Baseline serum RANKL levels may serve to predict remission in patients with rheumatoid arthritis treated with TNF antagonists” by Gonzalez-Alvaro, recently published in Annals of Rheumatic Diseases.1 Other reports have previously shown increased serum levels of RANKL (receptor activator for nuclear factor κB ligand), as well as of osteoprotegerin (OPG), in patients affected by rheumatoid arthritis (RA), and the upregulation of OPG has been usually interpreted as a compensatory mechanism to limit bone erosion due to RANKL activity.2–4 In addition, Gonzalez-Alvaro et al stated that low serum levels of baseline RANKL and the RANKL:OPG …

    View Full Text

    Footnotes

    • Competing interests: None.